ACE2 and neoplasm: Our group recently found that VEGF receptor tyrosine kinase inhibitors (TKI), such as Sunitinib or Axitinib, significantly downregulate ACE2 expression in tumor cells, and that the reduction in ACE2 activity is the driver for the development of resistance to such VEGF signaling inhibitors in various preclinical models of kidney cancer [13].